drugset / Trial / NCT05114720
Moxifloxacin in Adjuvant Treatment of Patients With Operable Breast Cancer
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary objective of this study is to compare disease-free survival (DFS) of patients with operable breast cancer randomised to treatment with standard adjuvant chemotherapy plus moxifloxacin or placebo.
Timeline
- Start
- 2021-11-11
- Primary completion
- 2025-11-27
- Completion
- 2025-11-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Moxifloxacin | Small molecule | 0.4 unknown | Oral |
| Comparator | Cyclophosphamide | Other / unclassified | 600 mg/m2 | Intravenous |
| Comparator | Cyclophosphamide | Other / unclassified | 1000 mg/m2 | Intravenous |
| Comparator | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Comparator | Docetaxel | Small molecule | 100 mg/m2 | Intravenous |
| Comparator | Doxorubicin | Other / unclassified | 60 mg/m2 | Intravenous |
| Comparator | Paclitaxel | Small molecule | 260 mg/m2 | Intravenous |